New Data Evaluating ABRAXANE In Early-Stage Breast Cancer And In Combination With Nov

[News]

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that multiple studies of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 31st Annual San Antonio Breast Cancer Symposium on December 10-14, 2008.

More... (http://www.medicalnewstoday.com/articles/132696.php)